Indonesian Pharmaceutical Biotechnology Introduces VIRADEF, a Solution for Travelers to Live Alongside Covid-19

Kapanlagi.com - According to data released by the COVID-19 Task Force, the number of new positive COVID-19 cases increased again in mid-January 2022 and continued to increase to more than 60 thousand in mid-February 2022. This number exceeds the number of new positive COVID-19 cases in July 2021.

President Joko Widodo has advised the public to be prepared to live alongside Covid-19 and to embrace this pandemic as an endemic. Based on this fact, PT Indonesian Pharmaceutical Biotechnology decided to participate in the ASTINDO travel fair at PIK Avenue from 3 to 6 March 2022.

PT Indonesian Pharmaceutical Biotechnology has opened an exhibition booth at booth number 10 for a noble purpose, which is to invite all Indonesian people, especially tourists and players in the tourism sector, to be ready to live alongside COVID-19 and to reduce the number of COVID-19 pandemic cases by implementing TRIPLE PROTECTION, namely Vaccination 4 Health Protocols 4 VIRADEF according to the recommendations of leading experts in allergy immunology.

"To be safe living alongside Covid-19, Viradef has been available since February and the quantity is sufficient to meet the needs of the community," said Dr. Izaak, Marketing Director of Indonesian Pharmaceutical Biotechnology, while attending the Astrindo Travel Fair at Pantai Indah Kapuk Avenue, North Jakarta, Friday (4/3/2022).

1. The Importance of Healthy Living with VIRADEF

Pharmaceutical Biotechnology Indonesia Supports the Government Through VIRADEF Products / Photo Credit: Personal Documentation

Realizing the increase of foreign tourists coming to Indonesia after the Covid 19 pandemic, PT Biotek Farmasi provides enlightenment to the tourism industry players, to give understanding to tourists about the importance of healthy living with VIRADEF.

"Viradef is safe for consumption for children aged 10 years to adults and does not have any harmful side effects to health. Because Viradef is a herbal medicine whose ingredients are imported from abroad," explained Dr. Izaak.

2. Already Obtained Marketing Authorization Number from BPOM

Pharmaceutical Biotechnology Indonesia Supports the Government Through VIRADEF Products / Photo Credit: Personal Documentation

VIRADEF product from PT Biotek Farmasi Indonesia is one form of the company's contribution in overcoming the COVID-19 pandemic in Indonesia. VIRADEF has obtained a Marketing Authorization Number from BPOM and based on the presentation by Prof. Dr. dr. Iris Rengganis Sp.PDKAI, a leading expert in the field of allergies and immunology, about this product.

It is mentioned that several scientific journals show that the composition in VIRADEF has various advantages based on Molecular Docking studies, namely it can inhibit TMPRSS2 which activates the entry of the Corona Virus into the body cells and inhibits MPro / 3CLpro which plays a role in the replication of the Corona Virus, thus helping to reduce the risk of infection by inhibiting the entry of the Corona Virus into the cells and helping to inhibit virus replication. This is the advantage of VIRADEF compared to other antiviral drugs that only work by inhibiting virus replication.

Clinical trials will be conducted as a continuation of the Molecular Docking study and PT Biotek Farmasi Indonesia is ready to conduct these clinical trials in the near future. Another advantage is that the components in this product can help reduce inflammation, increase cellular energy/ATP (Adenosine Tri Phosphate), and muscle strength, thus accelerating the body's recovery after infection.

(kpl/gtr)